Method for monitoring of medical treatment using pulse-echo ultrasound

Information

  • Patent Grant
  • 7846096
  • Patent Number
    7,846,096
  • Date Filed
    Monday, November 24, 2003
    21 years ago
  • Date Issued
    Tuesday, December 7, 2010
    14 years ago
Abstract
A method for ultrasound imaging of anatomical tissue. A first signal is received from a first imaging ultrasound wave which has been reflected from a location in the anatomical tissue during a first time period. A second signal is received from a second imaging ultrasound wave which has been reflected from the location in the anatomical tissue during a later second time period, following a discrete medical treatment. The second signal is subtracted from the first signal to form a difference signal. The difference signal may be scaled, spatially filtered, then used to generate an indication, the indication showing the effect of the medical treatment in the location in the anatomical tissue.
Description
FIELD OF THE INVENTION
Background of the Invention

Ultrasound medical systems and methods include ultrasound imaging of anatomical tissue to identify tissue for medical treatment. Ultrasound may also be used to medically treat and destroy unwanted tissue by heating the tissue. Imaging is done using low-intensity ultrasound waves, while medical treatment is performed with high-intensity ultrasound waves. High-intensity ultrasound waves, when focused at a focal zone a distance away from the ultrasound source, will substantially medically affect tissue in the focal zone. However, the high-intensity ultrasound will not substantially affect patient tissue outside the focal zone, such as tissue located between the ultrasound source and the focal zone. Other treatment regimes of interest include unfocused high-intensity ultrasound, wherein the ultrasound energy is distributed over a relatively broad region of tissue rather than being generally concentrated within a focal zone.


Ultrasound waves may be emitted and received by a transducer assembly. The transducer assembly may include a single element, or an array of elements acting together, to image the anatomical tissue and to ultrasonically ablate identified tissue. Transducer elements may employ a concave shape or an acoustic lens to focus ultrasound energy. Transducer arrays may include planar, concave or convex elements to focus or otherwise direct ultrasound energy. Further, such array elements may be electronically or mechanically controlled to steer and focus the ultrasound waves emitted by the array to a focal zone to provide three-dimensional medical ultrasound treatment of anatomical tissue. In some treatments the transducer is placed on the surface of the tissue for imaging and/or treatment of areas within the tissue. In other treatments the transducer is surrounded with a balloon which is expanded to contact the surface of the tissue by filling the balloon with a fluid such as a saline solution to provide acoustic coupling between the transducer and the tissue.


Examples of ultrasound medical systems and methods include: deploying an end effector having an ultrasound transducer outside the body to break up kidney stones inside the body; endoscopically inserting an end effector having an ultrasound transducer into the rectum to medically destroy prostate cancer; laparoscopically inserting an end effector having an ultrasound transducer into the abdominal cavity to destroy a cancerous liver tumor; intravenously inserting a catheter end effector having an ultrasound transducer into a vein in the arm and moving the catheter to the heart to medically destroy diseased heart tissue; and interstitially inserting a needle end effector having an ultrasound transducer into the tongue to medically destroy tissue to reduce tongue volume as a treatment for snoring. Methods for guiding an end effector to the target tissue include x-rays, Magnetic Resonance Images (“MRI”) and images produced using the ultrasound transducer itself.


Low-intensity ultrasound energy may be applied to unexposed anatomical tissue for the purpose of examining the tissue. Ultrasound pulses are emitted, and returning echoes are measured to determine the characteristics of the unexposed tissue. Variations in tissue structure and tissue boundaries have varying acoustic impedances, resulting in variations in the strength of ultrasound echoes. A common ultrasound imaging technique is known in the art as “B-Mode” wherein either a single ultrasound transducer is articulated or an array of ultrasound transducers is moved or electronically scanned to generate a two-dimensional image of an area of tissue. The generated image is comprised of a plurality of pixels, each pixel corresponding to a portion of the tissue area being examined. The varying strength of the echoes is preferably translated to a proportional pixel brightness. A cathode ray tube or liquid crystal display can be used to display a two-dimensional pixellated image of the tissue area being examined varying strength of the echoes is preferably translated to a proportional pixel brightness. A cathode ray tube or liquid crystal display can be used to display a two-dimensional pixellated image of the tissue area being examined.


When high-intensity ultrasound energy is applied to anatomical tissue, significant beneficial physiological effects may be produced in the tissue. For example, undesired anatomical tissue may be ablated by heating the tissue with high-intensity ultrasound energy. By focusing the ultrasound energy at one or more specific focusing zones within the tissue, thermal effects can be confined to a defined region that may be remote from the ultrasound transducer. The use of high-intensity focused ultrasound to ablate tissue presents many advantages, including: reduced patient trauma and pain; potentially reduced patient recovery time; elimination of the need for some surgical incisions and stitches; reduced or obviated need for general anesthesia; reduced exposure of non-targeted internal tissue; reduced risk of infection and other complications; avoidance of damage to non-targeted tissue; avoidance of harmful cumulative effects from the ultrasound energy on the surrounding non-target tissue; reduced treatment costs; minimal blood loss; and the ability for ultrasound treatments to be performed at non-hospital sites and/or on an out-patient basis.


Ultrasound treatment of anatomical tissue may involve the alternating use of both low-intensity imaging ultrasound and high-intensity treatment ultrasound. During such treatment, imaging is first performed to identify and locate the tissue to be treated. The identified tissue is then medically treated with high-intensity ultrasound energy for the purpose of ablating the tissue. After a period of exposure to high-intensity ultrasound, a subsequent image of the tissue is generated using low-intensity ultrasound energy to determine the results of the ultrasound treatment and provide visual guidance to the user to aid in subsequent treatments. This process of applying low-energy ultrasound to assist in guiding the position and focal point of the transducer, followed by high-energy ultrasound to ablate the undesired anatomical tissue, may continue until the undesired tissue has been completely ablated.


Although this conventional B-Mode ultrasound imaging provides an effective means for imaging tissue that is in a static state, imaging of the tissue becomes more problematic when used in conjunction with thermal high-intensity ultrasound treatment. As the tissue is ablated during treatment, the heating effects of ultrasound upon the tissue often result in qualitative changes in echo strength, causing brightness variations in the pixel display that do not consistently correspond spatially to the tissue being treated. These brightness variations result in an image display that does not represent the actual shape and size of the region of tissue that is being thermally modified by the treatment, introducing some visual ambiguity to the image.


Several methods are known for monitoring thermal ablation using B-Mode ultrasound imaging. Most of these are based on changes in the energy of ultrasound echoes, and include simple B-Mode displays of echo amplitude, estimates of tissue attenuation from analysis of distal shadowing, and quantification of changes in echo energy. Each of these methods have significant shortcomings because the tissue being treated can appear hyperechoic for reasons other than thermal ablation and because image changes must be qualitatively perceived by the user.


The most successful known methods for monitoring thermal ablation using ultrasound are based on analysis of changes in echo energy rather than a direct analysis of the echo energy. Automatic and quantitative displays of changes in echo energy or tissue attenuation are possible and can help users isolate thermally-induced changes from pre-existing echo characteristics. However, since such methods require integration of echoes over substantial regions of an image scan or “frame,” the resulting images are very limited in spatial resolution. Although energy increases (and therefore B-Mode brightness increases) correspond roughly to lesion (i.e., the thermally treated tissue) position, typically the shape and size of the mapped energy increases do not always spatially correspond to actual lesions, and sometimes are either absent or otherwise unapparent.


There is a need for an improved method of ultrasound imaging that can be utilized in conjunction with therapeutic ultrasound treatment that monitors the thermal effects of the treatment on targeted tissue with greater accuracy and resolution.


SUMMARY OF THE INVENTION

The present invention overcomes the limitations of the known art by mapping differences between a first and second echo signal, each signal being obtained at different instants of time. The first and second signals are typically separated by a small time interval. The first and second signals are processed, then a measure of the amplitude of the differences between the first and second signals is made (as contrasted with a measure of the differences in signal amplitude). This difference signal is then spatially filtered and scaled to quantify echo changes associated with changes in tissue state. Difference signals may be summed over multiple time periods to obtain a cumulative map of the changes in the tissue. The resulting signals may be used to generate an ultrasound image that is more representative of the tissue as treatment progresses, providing additional information about where thermal effects are occurring. This allows for verification of successful treatment and modification of unsuccessful treatment. Known ultrasound imaging and treatment transducers may be used, providing users with increased accuracy without a need for special end effectors.





BRIEF DESCRIPTION OF THE DRAWINGS

Further features of the present invention will become apparent to those skilled in the art to which the present invention relates from reading the following specification with reference to the accompanying drawings, in which:



FIG. 1 is a flow diagram providing an overview of an ultrasound treatment method according to an embodiment of the present invention;



FIG. 2 illustrates the relative amplitude and timing of ultrasound image frames and ultrasound treatments of the method of FIG. 1;



FIG. 3 is a flow diagram of a method for monitoring medical treatment of anatomical tissue using pulse-echo ultrasound according to an embodiment of the present invention;



FIG. 4 is a view of a first ultrasound signal on a time scale;



FIG. 5 is a view of a second ultrasound signal on a time scale;



FIG. 6 is a composite view of the signals of FIG. 4 and FIG. 5;



FIG. 7 is a view showing the difference signal computed from FIG. 4 and FIG. 5;



FIG. 8 is a view showing the absolute value of the difference signal of FIG. 7;



FIG. 9 is a view of the signal of FIG. 8 after filtering;



FIG. 10 is a flow diagram depicting a method for monitoring medical treatment of anatomical tissue using pulse-echo ultrasound according to an alternate embodiment of the present invention;



FIG. 11 illustrates the relative amplitude and timing of ultrasound image frames, image frame sets and ultrasound treatments of the method of FIG. 10;



FIG. 12 depicts a flow diagram of a method for monitoring medical treatment of anatomical tissue using pulse-echo ultrasound according to another alternate embodiment of the present invention;



FIG. 13 shows the relative amplitude and timing of ultrasound image frame sets, difference signals and ultrasound treatments of the method of FIG. 12;



FIG. 14 is a flow diagram of a method for monitoring medical treatment of anatomical tissue using pulse-echo ultrasound according to yet another alternate embodiment of the present invention; and



FIG. 15 shows the relative amplitude and timing of ultrasound image frames and ultrasound treatments of the method of FIG. 14.





DETAILED DESCRIPTION

An overview of an ultrasound treatment method 10 according to an embodiment of the present invention is shown in FIG. 1. The method begins at step 12 by positioning proximate the targeted anatomical tissue to be medically treated a transducer capable of transmitting and receiving ultrasound signals. Once the transducer is in position, treatment begins at step 14 by emitting a high-intensity ultrasound signal from the transducer. The high-intensity ultrasound signal medically treats the targeted tissue, such as (but not limited to) heating the tissue to ablate the material. At step 16 a low-intensity ultrasound signal, such as a B-Mode signal, is emitted from the transducer and the reflected signals are received to form a first image frame F1. It is understood that the terminology “image” includes, without limitation, creating an image in a visual form and displayed, for example, on a monitor, screen or display, and creating an image in electronic form which, for example, can be used by a computer without first being displayed in visual form. After the first image frame F1 is received at step 16, a predetermined waiting period is executed at step 18 before proceeding further. It is to be understood that the predetermined waiting period may vary in value from zero seconds upwardly to a maximum of several seconds, but preferably is in the range of milliseconds. After the predetermined wait period has been completed, a low intensity ultrasound signal is again emitted from the transducer and a second image frame F2 is received at step 20. At step 22 a difference signal is derived from the image frames F1 and F2, as will be discussed in greater detail below. The difference signal of step 22 is displayed as an image at step 24 to obtain a visual indication of the tissue change as a result of the medical treatment of step 14. It should be noted that the visual indication of the tissue change provided by the present invention differs from the post-treatment image of the prior art in that the present invention provides an image showing echo differences in contrast to echos from the target tissue. The image of echo differences can indicate whether treatment is complete. If treatment is complete at step 26 (for example, the targeted tissue has been fully ablated), the method is ended at step 28. However, if the tissue requires additional treatment, the transducer may be re-positioned at step 30. The method then returns to step 14 to continue medical treatment of the targeted tissue.


Referring additionally to FIG. 2, the method of FIG. 1 is illustrated in relation to a time scale t. The targeted tissue is medically treated with a relatively high-intensity ultrasound signal as at step 14. Then, at step 16 a relatively low-intensity B-Mode image scan frame F1 is received. After a predetermined off-time, as at step 18, a second image frame F2 is received, as at step 20. The image frames F1 and F2 each contain a signal representing the same portion of the target tissue. For each image frame, a number of A-lines of raw echo signal data are received, the number of each line corresponding to azimuthal position and the signal time corresponding to depth.


Referring now to FIG. 3 in combination with FIGS. 1 and 2, a method for monitoring medical treatment of anatomical tissue including, but not limited to, thermal ablation according to an embodiment of the present invention is depicted. An ultrasound transducer is positioned proximate the targeted anatomical tissue. The tissue may then be medically treated such as by ablation using high-intensity ultrasound waves for a period of time as at step 14. At step 16 a first image frame F1 (such as is illustrated in FIG. 4) is received. The image frame may optionally be stored electronically, such as in a computer, magnetic media and solid-state memory. A second image frame F2, separated from F1 by a fixed time interval of step 18, is received at step 20. An example image frame F2 is illustrated in FIG. 5. A difference signal is then derived at step 22 by means of steps 32-38. The raw echo signals of frames F1 and F2 may be processed at step 32, such as to obtain complex analytic signals by means of a Hilbert transformation. A difference signal may then be derived by subtracting the signal of image frame F2 from the signal of F1 at step 34. The difference signal of step 34 may take into account both phase and amplitude differences between F1 and F2, computing the amplitude of the signal differences (as opposed to differences in signal amplitude) of F1 and F2. A composite illustration of image frames F1 and F2 is shown in FIG. 6, while the derived difference signal is depicted in FIG. 7. At step 36 the difference signal may be scaled to a convenient value, such as the mean squared value of the difference signal, the mean squared value of one of the original echo signals, or a mathematical constant. As an example, a signal representing the scaled absolute value of the difference signal of FIG. 7 is shown in FIG. 8. Other functions of the difference signal, such as its squared absolute value or logarithm, may similarly be employed. Still other scaling algorithms may use the amplitude and/or phase of the first and second signals to enhance differences between the first and second signals. Details of such algorithms are left to the skilled artisan. At step 38 the difference signal is spatially filtered, as depicted in FIG. 9, to smooth small-scale random variations. Spatial filtering of the scaled difference signal is represented by Equation 1.







Ψ


(

x
,
z

)


=




-









-







w


(


x
-
x

,

z
-

z
0



)









p
0



(


x
0

,

z
0


)


-


p
1



(


x
0

,

z
0


)





2









x
0










z
0










Equation 1


In Equation 1 Ψ is a spatial difference map (image) of the scaled and filtered difference signal. The filtering may be performed by convolution of the scaled difference signal with a two-dimensional window w. This convolution may be efficiently performed through the use of two-dimensional Fast Fourier Transform (“FFT”) operations.


The difference signal may be normalized to have a maximum value of 1. This approach would result in a spatial map of the echo decorrelation, similar to measures of turbulence in color Doppler imaging systems. However, instead of examining echo decorrelation (a normalized measure of echo differences), a non-normalized map is considered preferable for the present invention because the echo difference is then enhanced in regions of greater echogenicity. Since hyperechoicity is one correlate to tissue ablation, this feature increases the specificity of the method for monitoring thermal ablative medical treatment by providing an image with greater detail.


The spatially filtered signal of FIG. 9 is then displayed as an image at step 24 (see FIG. 3), in any manner previously discussed.


In a second embodiment of the present invention, ultrasound images may be generated as depicted in FIGS. 10 and 11. At step 40 the tissue is medically treated with high-intensity ultrasound waves. At step 42 a succession of image frames, depicted as F1, F2, . . . Fn, are received. The image frames F1, F2, . . . Fn each contain a signal representing the same portion of the target tissue. At step 44 the image frames F1, F2, . . . Fn are mathematically grouped, such as by summing or averaging, to form a first image frame set labeled FS1, as shown in FIG. 11. After waiting a predetermined amount of time, as at step 46, a second set of image frames F1, F2, . . . Fn are received at step 48. At step 50 the second set of image frames F1, F2, . . . Fn are mathematically grouped, such as by summing or averaging, to form a second image frame set FS2 as shown in FIG. 11. The raw echo signals of image frame sets FS1 and FS2 may be processed at step 52, such as to derive complex analytic signals by means of a Hilbert transformation. The signal of image frame set FS2 is then subtracted from the signal of image frame set FS1 at step 54 to derive a difference signal. The difference signal may take into account both phase and amplitude differences between FS1 and FS2, computing the amplitude of the signal differences (as opposed to differences in signal amplitude) of FS1 and FS2. At step 56 the difference signal may be scaled to a convenient value using any scaling methods and algorithms, previously described or otherwise. At step 58 the difference signal is spatially filtered to smooth small-scale random variations before being displayed as an image at step 59. This embodiment of the present invention may provide a more robust map of the backscatter changes by reducing the influence of random signal variations caused by rapid transient effects such as violent bubble activity produced during tissue ablation.


In a third embodiment of the present invention, smoothing of the image signal may alternatively be accomplished by using a plurality of image frames, as illustrated in FIGS. 12 and 13. The tissue is medically treated at step 60, then a set of image frames F1, F2, . . . Fn are received at step 62. A plurality of difference signals D1, D2, . . . Dn are computed at step 64. It should be noted that the difference signals may be computed using various arrangements of pairs of image frames. For example, difference signal D1 may be formed by subtracting F2 from F1; likewise, D2 may be formed by subtracting F3 from F2, as shown in FIG. 13. Other arrangements of image frame pairs may also be used, including (but not limited to) odd-numbered image frames (i.e., subtracting F3 from F1, etc.) and even-numbered image frames (i.e., subtracting F4 from F2, etc.). The pairings may be interlaced (i.e., subtracting F2 from F1, subtracting F3 from F2, etc.) or sequential (i.e., subtracting F2 from F1, F4 from F3, etc.). An indication or image may be displayed at step 66, showing at least one of the difference signals D1, D2, . . . Dn. At step 68 the difference signals D1, D2, . . . Dn may be further processed, such as by averaging, to reduce artifactual content. The averaged signal, denoted as D, may also be displayed as an image, as at step 70. The averaged signals may themselves be cumulatively summed, as at step 72, to provide a view of the results of successive medical treatments 60. The summed averages may be displayed at step 74. If treatment is determined to be complete at step 76, the method is ended at step 78. However, if the tissue appears to require additional treatment, the transducer may be re-positioned at step 80. The method is then repeated beginning at step 60 to continue treatment of the targeted tissue.


A fourth embodiment of the present invention is shown in FIGS. 14 and 15 wherein a difference signal is derived using imaging frames generated both before and after medical treatment. At step 82 the ultrasound transducer is positioned proximate the targeted tissue to be medically treated. At step 84 a pre-treatment image frame F1 is generated from received ultrasound signals. Then, at step 86 the tissue is subject to a quantum of medical treatment, such as by ablating the tissue. After a quantum of medical treatment is administered, a second image frame F2 is generated at step 88. A difference signal is derived at step 90, using the data contained in image frames F1 and F2 in the same manner as previously described. An indication or image of the difference signal may be displayed at step 92. If treatment is determined to be complete at step 94, the method is ended at step 96. However, if the targeted tissue is determined to require additional treatment, the transducer may be re-positioned as necessary at step 98. The method is then repeated and a subsequent quantum of treatment is administered beginning at step 84.


An expected difficulty for the present invention is artifactual backscatter change due to tissue motion artifacts. This difficulty can be largely overcome by several features of the method. First, backscatter differences can be computed between image frames closely spaced in time. If the tissue moves only a small amount during the interval, motion artifacts are then small. Second, artifacts due to axial tissue motion can be removed effectively by phase compensation during signal processing. That is, before computation of the signal difference, one of the complex image frames is multiplied by a phase compensation function e−iθ, where θ is the low-pass filtered phase of the conjugate product of the two complex image frames. The resulting signal difference is then computed, for example, using Equation 2:






Ψ
=




-









-







w


(

x
,
z

)









p
0



(

x
,
z

)


-



p
1



(

x
,
z

)







-








ϖ
0


δ





t






2








x








z









Equation 2


which is an improved echo difference map with reduced tissue motion artifacts.


It is understood that one or more of the previously-described embodiments, expressions of embodiments, examples, methods, etc. can be combined with any one or more of the other previously-described embodiments, expressions of embodiments, examples, methods, etc. For example, and without limitation, any of the ultrasound transducers may be used with other methods of medical treatment, such as producing images to aid in tissue ablation by means of Radio Frequency (RF) and laser energy, various non-ablative ultrasound medical treatments, and various ultrasound imaging applications.


The foregoing description of several expressions of embodiments and methods of the invention has been presented for purposes of illustration. It is not intended to be exhaustive or to limit the present invention to the precise forms and procedures disclosed, and obviously many modifications and variations are possible in light of the above teaching. It is intended that the scope the invention be defined by the claims appended hereto.

Claims
  • 1. A method for ultrasound imaging of anatomical tissue using an ultrasound transducer, comprising the steps of: a) positioning the ultrasound transducer relative to the anatomical tissue;b) receiving a time-varying first signal of a first imaging ultrasound wave which has been reflected from a location in the anatomical tissue during a first time period, the first imaging ultrasound wave being generated by the ultrasound transducer;c) receiving a time-varying second signal of a second imaging ultrasound wave which has been reflected from the location in the anatomical tissue at a later second time period following a discrete ultrasound medical treatment, the second imaging ultrasound wave being generated by the ultrasound transducer;d) subtracting the second signal from the first signal to derive a time-varying difference signal; ande) generating an indication from the difference signal, the indication showing the effect of the discrete ultrasound medical treatment in the location in the anatomical tissue.
  • 2. The method of claim 1 wherein the first and second signals are received after the discrete ultrasound medical treatment has been completed.
  • 3. The method of claim 1 wherein the first signal is received before the discrete ultrasound medical treatment, and the second signal is received after the discrete ultrasound medical treatment has been completed.
  • 4. The method of claim 1, further comprising the step of processing the first and second signals.
  • 5. The method of claim 4, further comprising the step of multiplying at least one of the first and second signals by a phase compensation function to reduce motion artifacts.
  • 6. The method of claim 1, further comprising the step of scaling the difference signal.
  • 7. The method of claim 6 wherein the difference signal is scaled by squaring the amplitude of the difference signal.
  • 8. The method of claim 1, further comprising the step of spatially filtering the difference signal.
  • 9. The method of claim 1, wherein the ultrasound medical treatment includes tissue ablation.
  • 10. The method of claim 1, also including the steps a) through d) for different locations to image the anatomical tissue, wherein the image includes medically-treated locations and medically-untreated locations of the anatomical tissue.
  • 11. The method of claim 1, further comprising the step of combining the difference signal image with a second image of the location in the anatomical tissue.
  • 12. The method of claim 11 wherein the second image is generated using a B-Mode ultrasound scan.
  • 13. A method for ultrasound imaging of anatomical tissue using an ultrasound transducer, comprising the steps of: a) positioning the ultrasound transducer relative to the anatomical tissue;b) receiving a time-varying first signal of a first imaging ultrasound wave which has been reflected from a location in the anatomical tissue during a first time period, the first imaging ultrasound wave being generated by the ultrasound transducer;c) receiving a time-varying second signal of a second imaging ultrasound wave which has been reflected from the location in the anatomical tissue at a later second time period following a discrete ultrasound medical treatment, the second imaging ultrasound wave being generated by the ultrasound transducer;d) processing the first and second signals;e) subtracting the second signal from the first signal to derive a time-varying difference signal;f) scaling the difference signal;g) spatially filtering the difference signal; andh) generating an indication from the difference signal, the indication showing the effect of the discrete ultrasound medical treatment in the location in the anatomical tissue.
  • 14. The method of claim 13 wherein the first and second signals are received after the discrete ultrasound medical treatment has been completed.
  • 15. The method of claim 13 wherein the first signal is received before the discrete ultrasound medical treatment and the second signal is received after the discrete ultrasound medical treatment.
  • 16. A method for ultrasound imaging of anatomical tissue using an ultrasound transducer, comprising the steps of: a) positioning the ultrasound transducer relative to the anatomical tissue;b) receiving a first set of image frames comprising a plurality of time-varying imaging ultrasound wave signals which have been reflected from a location in the anatomical tissue during a first period of time;c) receiving a second set of image frames comprising a plurality of time-varying imaging ultrasound wave signals which have been reflected from the location in the anatomical tissue during a later second period of time following a discrete ultrasound medical treatment;d) subtracting the imaging ultrasound signals of the second set of image frames from the imaging ultrasound signals of the first set of image frames to derive a time-varying difference signal; ande) generating an indication from the difference signal, the indication showing the effect of the discrete ultrasound medical treatment in the location in the anatomical tissue.
  • 17. The method of claim 16 wherein the first and second sets of image frames are received after the discrete ultrasound medical treatment has been completed.
  • 18. The method of claim 16 wherein the first set of image frames is received before the discrete ultrasound medical treatment, and the second set of image frames is received after the discrete ultrasound medical treatment.
  • 19. The method of claim 16, further comprising the step of processing the first and second sets of signals.
  • 20. The method of claim 16, further comprising the step of scaling the difference signal.
  • 21. The method of claim 20 wherein the difference signal is scaled by squaring the amplitude of the difference signal.
  • 22. The method of claim 16, further comprising the step of spatially filtering
  • 23. The method of claim 16, wherein the ultrasound medical treatment includes tissue ablation.
  • 24. The method of claim 16, also including the steps a) through d) for different locations to image the anatomical tissue, wherein the image includes medically-treated locations and medically-untreated locations of the anatomical tissue.
  • 25. A method for ultrasound imaging of anatomical tissue using an ultrasound transducer, comprising the steps of: a) positioning the ultrasound transducer relative to the anatomical tissueb) receiving a first set of image frames comprising a plurality of time-varying imaging ultrasound wave signals which have been reflected from a location in the anatomical tissue during a first period of time;c) receiving a second set of image frames comprising a plurality of time-varying imaging ultrasound wave signals which have been reflected from the location in the anatomical tissue during a later second period of time following a discrete ultrasound medical treatment;d) processing the first and second sets of signals;e) subtracting the imaging ultrasound signals of the second set of image frames from the imaging ultrasound signals of the first set of image frames to derive a time-varying difference signal;f) scaling the difference signal;g) spatially filtering the difference signal; andh) generating an indication from the difference signal, the indication showing the effect of the discrete ultrasound medical treatment in the location in the anatomical tissue.
  • 26. The method of claim 25 wherein the first and second sets of image frames are received after the discrete ultrasound medical treatment has been completed.
  • 27. The method of claim 25 wherein the first set of image frames is received before the discrete ultrasound medical treatment, and the second set of image frames is received after the discrete ultrasound medical treatment.
  • 28. The method of claim 25 wherein the ultrasound medical treatment includes tissue ablation.
  • 29. The method of claim 25, also including the steps a) through g) for different locations to image the anatomical tissue, wherein the image includes medically-treated locations and medically-untreated locations of the anatomical tissue.
  • 30. A method for ultrasound imaging of anatomical tissue using an ultrasound transducer, comprising the steps of: a) positioning the ultrasound transducer relative to the anatomical tissue;b) providing a discrete ultrasound medical treatment to the anatomical tissue;c) receiving a set of image frames comprising a plurality of time-varying imaging ultrasound wave signals which have been reflected from a location in the anatomical tissue;d) pairing together a plurality of image frames, each pair comprising a first image frame and a second image frame such that the second image frame has been reflected from a location in the anatomical tissue at a later time than the first image frame;e) subtracting the signals of the second image frame from the signals of the first image frame, for each pair of image frames in the image frame set, to derive a set of time-varying difference signals;f) using at least one difference signal to generate an indication showing the effect of the discrete ultrasound medical treatment in the location in the anatomical tissue; andg) repeating steps a) through e) until medical treatment is completed.
  • 31. The method of claim 30, further comprising the steps of: a) computing an average of the set of difference signals; andb) using the average of the set of difference signals to generate an indication showing the effect of the discrete ultrasound medical treatment in the location in the anatomical tissue.
  • 32. The method of claim 31, further comprising the steps of: a) cumulatively summing the averages of the set of difference signals; andb) using the cumulative sum of averages of the set of difference signals to generate an indication showing the effect of the discrete ultrasound medical treatment in the location in the anatomical tissue.
Parent Case Info

This is a continuation-in-part of application Ser. No. 10/153,241, filed May 22, 2002, now abandoned which claims priority to provisional application Ser. No. 60/294,135 filed May 29, 2001. The present invention relates generally to ultrasound, and more particularly, to an ultrasound medical imaging method.

US Referenced Citations (337)
Number Name Date Kind
3168659 Bayre et al. Feb 1965 A
3779234 Eggleton et al. Dec 1973 A
3902501 Citron et al. Sep 1975 A
3927557 Viertl Dec 1975 A
4211948 Smith et al. Jul 1980 A
4315514 Drewes et al. Feb 1982 A
4323077 Smith Apr 1982 A
4484569 Driller et al. Nov 1984 A
4646756 Watmough et al. Mar 1987 A
4748985 Nagasaki Jun 1988 A
4757820 Itoh Jul 1988 A
4787394 Ogura Nov 1988 A
4790329 Simon Dec 1988 A
4798215 Turner Jan 1989 A
4818954 Flachenecker et al. Apr 1989 A
4844080 Frass et al. Jul 1989 A
4858613 Fry et al. Aug 1989 A
4932414 Coleman et al. Jun 1990 A
4937767 Reuschel et al. Jun 1990 A
4951653 Fry et al. Aug 1990 A
4955365 Fry et al. Sep 1990 A
4955366 Uchiyama et al. Sep 1990 A
4960107 Aida et al. Oct 1990 A
4960109 Lele Oct 1990 A
4984575 Uchiyama et al. Jan 1991 A
4986275 Ishida et al. Jan 1991 A
5005580 Okazaki Apr 1991 A
RE33590 Dory May 1991 E
5015929 Cathignol et al. May 1991 A
5031626 Hassler et al. Jul 1991 A
5036855 Fry et al. Aug 1991 A
5042486 Pfeiler et al. Aug 1991 A
5054470 Fry et al. Oct 1991 A
5065740 Itoh Nov 1991 A
5078144 Sekino et al. Jan 1992 A
5080101 Dory Jan 1992 A
5080102 Dory Jan 1992 A
5095906 Ema Mar 1992 A
5095907 Kudo et al. Mar 1992 A
5117832 Sanghvi et al. Jun 1992 A
5143073 Dory Sep 1992 A
5143074 Dory Sep 1992 A
5148809 Biegeleisen-Knight et al. Sep 1992 A
5149319 Unger Sep 1992 A
5150711 Dory Sep 1992 A
5150712 Dory Sep 1992 A
5158070 Dory Oct 1992 A
5158071 Umemura et al. Oct 1992 A
5203333 Nomura Apr 1993 A
5209221 Riedlinger May 1993 A
5238007 Giele et al. Aug 1993 A
5240005 Viebach Aug 1993 A
5242437 Everett et al. Sep 1993 A
5295484 Marcus et al. Mar 1994 A
5304115 Pflueger et al. Apr 1994 A
5311869 Okazaki May 1994 A
5345940 Seward et al. Sep 1994 A
5348017 Thornton et al. Sep 1994 A
5354258 Dory Oct 1994 A
5370121 Reichenberger et al. Dec 1994 A
5391140 Schaetzle et al. Feb 1995 A
5391197 Burdette et al. Feb 1995 A
5398690 Batten et al. Mar 1995 A
5398691 Martin et al. Mar 1995 A
5402792 Kimura Apr 1995 A
5409002 Pell Apr 1995 A
5419335 Hartmann et al. May 1995 A
5421338 Crowley et al. Jun 1995 A
5431663 Carter Jul 1995 A
5435304 Oppelt et al. Jul 1995 A
5435311 Umemura et al. Jul 1995 A
5443069 Schaetzle Aug 1995 A
5448994 Iinuma Sep 1995 A
5458597 Edwards et al. Oct 1995 A
5465724 Sliwa et al. Nov 1995 A
5471988 Fujio et al. Dec 1995 A
5474071 Chapelon et al. Dec 1995 A
5485839 Aida et al. Jan 1996 A
5492126 Hennige et al. Feb 1996 A
5500012 Brucker et al. Mar 1996 A
5501655 Rolt et al. Mar 1996 A
5514085 Yoon May 1996 A
5514130 Baker May 1996 A
5520188 Hennige et al. May 1996 A
5522869 Burdette et al. Jun 1996 A
5524620 Rosenschein Jun 1996 A
5526815 Granz et al. Jun 1996 A
5526816 Arditi Jun 1996 A
5526822 Burbank et al. Jun 1996 A
5540656 Pflueger et al. Jul 1996 A
5545195 Lennox et al. Aug 1996 A
5547459 Kaufman et al. Aug 1996 A
5549638 Burdette Aug 1996 A
5553618 Suzuki et al. Sep 1996 A
5558092 Unger et al. Sep 1996 A
5569241 Edwards Oct 1996 A
5571088 Lennox et al. Nov 1996 A
5573497 Chapelon Nov 1996 A
5575288 Sliwa et al. Nov 1996 A
5575772 Lennox Nov 1996 A
5575789 Bell et al. Nov 1996 A
5582588 Sakurai et al. Dec 1996 A
5588432 Crowley Dec 1996 A
5590657 Cain et al. Jan 1997 A
5596991 Tanaka Jan 1997 A
5601526 Chapelon et al. Feb 1997 A
5603326 Richter Feb 1997 A
5606975 Liang et al. Mar 1997 A
5620479 Diederich Apr 1997 A
5624382 Oppelt et al. Apr 1997 A
5626607 Malecki et al. May 1997 A
5628743 Cimino May 1997 A
5630837 Crowley May 1997 A
5643179 Fujimoto Jul 1997 A
5649547 Ritchart et al. Jul 1997 A
5657760 Ying et al. Aug 1997 A
5665054 Dory Sep 1997 A
5666954 Chapelon et al. Sep 1997 A
5676692 Sanghvi et al. Oct 1997 A
5687729 Schaetzle Nov 1997 A
5694936 Fujimoto et al. Dec 1997 A
5697897 Buchholtz et al. Dec 1997 A
5699804 Rattner Dec 1997 A
5699805 Seward et al. Dec 1997 A
5703922 Rattner Dec 1997 A
5715825 Crowley Feb 1998 A
5720287 Chapelon et al. Feb 1998 A
5722411 Suzuki et al. Mar 1998 A
5728062 Brisken Mar 1998 A
5733315 Burdette et al. Mar 1998 A
5735280 Sherman et al. Apr 1998 A
5735796 Granz et al. Apr 1998 A
5738635 Chapelon et al. Apr 1998 A
5743862 Izumi Apr 1998 A
5743863 Chapelon Apr 1998 A
5746224 Edwards May 1998 A
5759154 Hoyns Jun 1998 A
5759162 Oppelt et al. Jun 1998 A
5762066 Law et al. Jun 1998 A
5769086 Ritchart et al. Jun 1998 A
5769790 Watkins et al. Jun 1998 A
5771896 Sliwa et al. Jun 1998 A
5776092 Farin et al. Jul 1998 A
5779643 Lum et al. Jul 1998 A
5782764 Werne Jul 1998 A
5785705 Baker Jul 1998 A
5788636 Curley Aug 1998 A
5800379 Edwards Sep 1998 A
5807308 Edwards Sep 1998 A
5810742 Pearlman Sep 1998 A
5817021 Reichenberger Oct 1998 A
5817049 Edwards Oct 1998 A
5820580 Edwards et al. Oct 1998 A
5823962 Schaetzle et al. Oct 1998 A
5836896 Rosenschein Nov 1998 A
5840022 Richter Nov 1998 A
5840031 Crowley Nov 1998 A
5860974 Abele Jan 1999 A
5873828 Fujio et al. Feb 1999 A
5873845 Cline et al. Feb 1999 A
5873902 Sanghvi et al. Feb 1999 A
5876399 Chia et al. Mar 1999 A
5882302 Driscoll, Jr. et al. Mar 1999 A
5893835 Witt et al. Apr 1999 A
5895356 Andrus et al. Apr 1999 A
5897495 Aida et al. Apr 1999 A
5906580 Kline-Schoder et al. May 1999 A
5928169 Schatzle et al. Jul 1999 A
5931805 Brisken Aug 1999 A
5931848 Saadat Aug 1999 A
5938600 Van Vaals et al. Aug 1999 A
5938608 Bieger et al. Aug 1999 A
5944663 Kuth et al. Aug 1999 A
5964755 Edwards Oct 1999 A
5976105 Marcove et al. Nov 1999 A
5979453 Savage et al. Nov 1999 A
5984881 Ishibashi et al. Nov 1999 A
5984882 Rosenschein et al. Nov 1999 A
5987523 Hind et al. Nov 1999 A
5993389 Driscoll, Jr. et al. Nov 1999 A
5997534 Tu et al. Dec 1999 A
6001069 Tachibana et al. Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6007499 Martin et al. Dec 1999 A
6010531 Donlon et al. Jan 2000 A
6013031 Mendlein et al. Jan 2000 A
6022319 Willard et al. Feb 2000 A
6024718 Chen et al. Feb 2000 A
6024740 Lesh et al. Feb 2000 A
6030344 Guracar et al. Feb 2000 A
6039689 Lizzi Mar 2000 A
6042556 Beach et al. Mar 2000 A
6050943 Slayton et al. Apr 2000 A
6053868 Geistert et al. Apr 2000 A
6059731 Seward et al. May 2000 A
6063050 Manna et al. May 2000 A
6066123 Li et al. May 2000 A
6071238 Chapelon et al. Jun 2000 A
6071239 Cribbs et al. Jun 2000 A
6071279 Whayne et al. Jun 2000 A
6083159 Driscoll et al. Jul 2000 A
6086535 Ishibashi et al. Jul 2000 A
6086539 Guracar et al. Jul 2000 A
6088613 Unger Jul 2000 A
6093149 Guracar et al. Jul 2000 A
6106470 Geiser et al. Aug 2000 A
6106517 Zupkas Aug 2000 A
6110118 Guracar et al. Aug 2000 A
6112123 Kelleher et al. Aug 2000 A
6113558 Rosenschein et al. Sep 2000 A
6117101 Diederich et al. Sep 2000 A
6128958 Cain Oct 2000 A
6135963 Haider Oct 2000 A
6135971 Hutchinson et al. Oct 2000 A
6138513 Barabash et al. Oct 2000 A
6149598 Tanaka Nov 2000 A
6156029 Mueller Dec 2000 A
6159207 Yoon Dec 2000 A
6171248 Hossack et al. Jan 2001 B1
6176842 Tachibana et al. Jan 2001 B1
6183469 Thapliyal et al. Feb 2001 B1
6193664 Guracar et al. Feb 2001 B1
6193709 Miyawaki et al. Feb 2001 B1
6206843 Iger et al. Mar 2001 B1
6210330 Tepper Apr 2001 B1
6216704 Ingle et al. Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6221014 Bauer Apr 2001 B1
6231834 Unger et al. May 2001 B1
6241677 Guracar et al. Jun 2001 B1
6246898 Vesely et al. Jun 2001 B1
6258029 Guracar et al. Jul 2001 B1
6266552 Slettenmark Jul 2001 B1
6315723 Robinson et al. Nov 2001 B1
6322511 Guracar et al. Nov 2001 B1
6340348 Krishnan et al. Jan 2002 B1
6340352 Okada et al. Jan 2002 B1
6352532 Kramer et al. Mar 2002 B1
6361531 Hissong Mar 2002 B1
6371903 Blanc et al. Apr 2002 B1
6371973 Tepper Apr 2002 B1
6379320 Lafon et al. Apr 2002 B1
6425867 Vaezy et al. Jul 2002 B1
6428477 Mason Aug 2002 B1
6440147 Lee et al. Aug 2002 B1
6461314 Pant et al. Oct 2002 B1
6464640 Guracar et al. Oct 2002 B1
6482178 Andrews et al. Nov 2002 B1
6488626 Lizzi et al. Dec 2002 B1
6488630 Hand et al. Dec 2002 B1
6508774 Acker et al. Jan 2003 B1
6512957 Witte Jan 2003 B1
6521211 Unger et al. Feb 2003 B1
6533726 Lizzi et al. Mar 2003 B1
6540700 Fujimoto et al. Apr 2003 B1
6546934 Ingle et al. Apr 2003 B1
6562033 Shah et al. May 2003 B2
6575969 Rittman et al. Jun 2003 B1
6599245 Ma et al. Jul 2003 B1
6602251 Burbank et al. Aug 2003 B2
6613004 Vitek et al. Sep 2003 B1
6618620 Freundlich et al. Sep 2003 B1
6626855 Weng et al. Sep 2003 B1
6635054 Fjield et al. Oct 2003 B2
6638235 Miller et al. Oct 2003 B2
6641579 Bernardi et al. Nov 2003 B1
6645202 Pless et al. Nov 2003 B1
6659949 Lang et al. Dec 2003 B1
6669638 Miller et al. Dec 2003 B1
6673019 Kamiyama Jan 2004 B2
6682483 Abend et al. Jan 2004 B1
6702745 Smythe Mar 2004 B1
6716184 Vaezy et al. Apr 2004 B2
6719694 Weng et al. Apr 2004 B2
6726677 Flaherty et al. Apr 2004 B1
6764488 Burbank et al. Jul 2004 B1
6770070 Balbierz Aug 2004 B1
6887239 Elstrom et al. May 2005 B2
6902536 Manna et al. Jun 2005 B2
6921371 Wilson Jul 2005 B2
6936024 Houser Aug 2005 B1
6936048 Hurst Aug 2005 B2
6974417 Lockwood et al. Dec 2005 B2
7035166 Zimmerman et al. Apr 2006 B2
7037306 Podany et al. May 2006 B2
7063666 Weng et al. Jun 2006 B2
7078015 Unger Jul 2006 B2
7410469 Talish et al. Aug 2008 B1
20010007940 Tu et al. Jul 2001 A1
20010014805 Burbank et al. Aug 2001 A1
20010037073 White et al. Nov 2001 A1
20020065512 Fjield et al. May 2002 A1
20020068934 Edwards et al. Jun 2002 A1
20020087081 Serrano et al. Jul 2002 A1
20020087803 Jones et al. Jul 2002 A1
20020111662 Iaizzo et al. Aug 2002 A1
20020165579 Burbank et al. Nov 2002 A1
20020183371 Gordeev et al. Dec 2002 A1
20020183742 Carmel et al. Dec 2002 A1
20020193731 Myers et al. Dec 2002 A1
20030004434 Greco et al. Jan 2003 A1
20030013960 Makin et al. Jan 2003 A1
20030013971 Makin et al. Jan 2003 A1
20030014093 Makin Jan 2003 A1
20030018266 Makin et al. Jan 2003 A1
20030018358 Saadat Jan 2003 A1
20030028111 Vaezy et al. Feb 2003 A1
20030040698 Makin et al. Feb 2003 A1
20030047582 Sonnenschein et al. Mar 2003 A1
20030073907 Taylor Apr 2003 A1
20030109786 Irioka et al. Jun 2003 A1
20030120270 Acker Jun 2003 A1
20030120306 Burbank et al. Jun 2003 A1
20030144593 Whitmore et al. Jul 2003 A1
20030212331 Fenton et al. Nov 2003 A1
20030212332 Fenton et al. Nov 2003 A1
20030220568 Hansmann et al. Nov 2003 A1
20040006336 Swanson Jan 2004 A1
20040030268 Weng et al. Feb 2004 A1
20040041880 Ikeda et al. Mar 2004 A1
20040127791 Mast et al. Jul 2004 A1
20040143252 Hurst Jul 2004 A1
20050015107 O'Brien Jan 2005 A1
20050131298 Cai Jun 2005 A1
20050137520 Rule et al. Jun 2005 A1
20050228286 Messerly et al. Oct 2005 A1
20050240125 Makin et al. Oct 2005 A1
20050261585 Makin et al. Nov 2005 A1
20050261587 Makin et al. Nov 2005 A1
20050261588 Makin et al. Nov 2005 A1
20050261610 Mast et al. Nov 2005 A1
20050267488 Hare et al. Dec 2005 A1
20060052701 Carter et al. Mar 2006 A1
20060173348 Wilser et al. Aug 2006 A1
20060235306 Cotter et al. Oct 2006 A1
20070004984 Crum et al. Jan 2007 A1
20070021691 Nita et al. Jan 2007 A1
Foreign Referenced Citations (29)
Number Date Country
0897696 Feb 1999 EP
10-14967 Jan 1989 JP
04-307044 Oct 1992 JP
08-084470 Mar 1996 JP
08-084740 Apr 1996 JP
9098980 Apr 1997 JP
09-192139 Jul 1997 JP
10-216146 Aug 1998 JP
10-511477 Nov 1998 JP
11-313832 Nov 1999 JP
2000-116657 Apr 2000 JP
2000-126185 May 2000 JP
2000-126197 May 2000 JP
2000-237205 Sep 2000 JP
2001-104358 Apr 2001 JP
9529737 Nov 1995 WO
9729709 Aug 1997 WO
WO 9858588 Dec 1998 WO
9933500 Jul 1999 WO
0038580 Jul 2000 WO
WO 0134018 May 2001 WO
0143641 Jun 2001 WO
0145550 Jun 2001 WO
0145550 Dec 2001 WO
0197702 Dec 2001 WO
03075711 Sep 2003 WO
03075771 Sep 2003 WO
2005058138 Jun 2005 WO
2005072084 Aug 2005 WO
Related Publications (1)
Number Date Country
20040106870 A1 Jun 2004 US
Provisional Applications (1)
Number Date Country
60294135 May 2001 US
Continuation in Parts (1)
Number Date Country
Parent 10153241 May 2002 US
Child 10721034 US